RLAY: Relay Therapeutics Inc Price-to-Revenue Multiple

Relay Therapeutics (RLAY) optimizes innovation by outsourcing production and testing to third-party contractors. The price/sales ratio trend on the GURU.Markets website shows a peak, but 382.30 represents the current metric value. However, AI development carries risks of trial failures and high costs. Stable management with deep scientific expertise and liquidity mitigates these challenges, ensuring the development of targeted therapy.

RLAY Relay Corp Market Cap to Revenue (07/04/2022 - 11/13/2026)

Analytical breakdowns for Relay Pharma (RLAY)

- share price and consensus valuation forecast:

Price Performance Chart relaytx.com|RLAY - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Relay Pharma|RLAY - Enterprise Value

- book capitalization data:

Net Asset Value per Share Relay Therapeutics|RLAY - Company Net Assets|Market Cap to Book Value Multiple relaytx.com|RLAY - Company Total Assets

- debt obligations and liquidity statistics:

- earnings and multiples data:

RLAY - Net Profit|Expected Net Profit Relay Therapeutics|RLAY - Price to Earnings Ratio|Future Price to Earnings Multiple Relay Therapeutics Inc|RLAY - PEG Multiple|EV/EBITDA Multiple Relay Pharma|RLAY - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Relay Therapeutics|RLAY - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months relaytx.com|RLAY - Earnings per share growth in current year|Expected earnings per share trend next year Relay Therapeutics

- sales revenue and business income indicators:

RLAY - Revenue and Sales Volume|Company Expected Sales Volume relaytx.com|RLAY - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Relay Pharma

Summary company analytics:relaytx.com, RLAY

The competitiveness of Relay Therapeutics (RLAY) is based on the precision of the Dynamo platform, making the price-to-sales ratio a key indicator of market expectations for future successes in oncology biotech. This ratio correlates the total business value with its actual revenue, allowing investors to assess the premium paid for clinical trial potential and partnerships with Roche relative to current cash flows.

Who Relay Therapeutics competes with

GMAB (genmab.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EXEL (Exelixis)|Price-to-Revenue Multiple Nuvalent Inc|Kymera Therapeutics Inc - P/S Multiple|Price to Sales IDEAYA Corp|ELVN (Enliven Therapeutics) - Market Cap to Revenue|ORIC: Market Cap to Sales Volume|NRIX (Nurix Therapeutics, Inc.) - P/S Multiple|Price to Sales Tyra Biosciences Inc TYRA|P/S Multiple VSTM|Monte Rosa Corp - Market Cap to Revenue Ratio|Cullinan Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio IMRX|CCCC: Market Cap to Revenue|Black Diamond Therapeutics, Inc. - Market Cap to Sales Volume|RPTX: P/S Multiple|PMV Pharmaceuticals, Inc - Market Capitalization-to-Revenue Ratio|KPTI (Karyopharm Therapeutics, Inc.) - P/S Multiple|Price to Sales Propanc Biopharma, Inc. PPCB|Price-to-Revenue Ratio Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALRN (Aileron Therapeutics, Inc.)|P/S Multiple Blueprint Medicines Corp. BPMC|GLYC - Price-to-Revenue Ratio|Price-to-Sales Ratio SWTX